A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats

Biol Pharm Bull. 2012;35(2):139-44. doi: 10.1248/bpb.35.139.


Curcumin is an inhibitor of p300 histone acetyltransferase activity, which is associated with the deterioration of heart failure. We reported that native curcumin, at a dosage of 50 mg/kg, prevented deterioration of the systolic function in rat models of heart failure. To achieve more efficient oral pharmacological therapy against heart failure by curcumin, we have developed a novel drug delivery system (DDS) which markedly increases plasma curcumin levels. At the dosage of 0.5 mg/kg, DDS curcumin but not native curcumin restored left ventricular fractional shortening in post-myocardial infarction rats. Thus, our DDS strategy will be applicable to the clinical setting in humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Cardiotonic Agents / administration & dosage*
  • Cardiotonic Agents / pharmacokinetics
  • Curcumin / administration & dosage*
  • Curcumin / pharmacokinetics
  • Disease Models, Animal
  • Drug Delivery Systems
  • Gum Arabic / administration & dosage
  • Heart Failure / drug therapy*
  • Heart Failure / pathology
  • Heart Failure / physiopathology
  • Hemodynamics
  • Intestinal Absorption / drug effects
  • Male
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / pathology
  • Myocardial Infarction / physiopathology
  • Plant Gums / administration & dosage*
  • Rats
  • Rats, Sprague-Dawley
  • p300-CBP Transcription Factors / antagonists & inhibitors


  • Cardiotonic Agents
  • Plant Gums
  • Gum Arabic
  • p300-CBP Transcription Factors
  • p300-CBP-associated factor
  • Curcumin
  • gum ghatti